Acceptance rate of 98% over two decades of publications experience, slide kits (for symposia, CME or training),
in-house poster production.
Peer-reviewed journals (original scientific research, primary and secondary clinical research, systematic reviews)
Scientific /clinical study results – content development and in-house graphic design and printing
Senior writers are ISMPP Certified Medical Publication Professionals™
Every writer has
minimum industry experienceSenior writers' experience ranges from
up to 40 years
Time at Micron
Average time of being in a writing position at Micron
with a range of 3 to 20 years
Our medical writing adheres to Good Publication Practice (GPP) and the recommendations of the International Committee of Medical Journal Editors (ICMJE).
Our position statement describes how we ensure that all of our work is of the highest scientific integrity and is consistent with best practice.
Our Client Relationships
We have a collaborative partnership approach to working with our clients.
We believe this is the most efficient route towards achieving the client’s goals. Here’s what a few of our clients have said about us…
Our team’s detailed knowledge of anti-infectives is complemented by our writers’ experience of many different clinical indications and areas of scientific research, summarised in the table below.
|Clinical Indications and Scientific Research
|Community-acquired pneumonia | Healthcare-associated pneumonia | Ventilator-associated pneumonia | Acute bacterial skin and skin structure infections | Intra-abdominal infections | Urinary tract infections | Hepatitis
|Interventional cardiology | Chronic heart failure | Hypertension | Angina
|Diabetes (type I & II) | Obesity | Cushings syndrome | Pituitary gland tumours | Female ovarian function
|Inflammatory bowel disease (IBD) | Irritable bowel syndrome (IBS)
|Sickle cell anaemia | Acute/chronic clotting factor deficiency | Acute/chronic thrombocytopaenia
|Auto-immune diseases (rheumatoid arthritis, immune thrombocytopenic purpura [ITP]) | Inflammation signalling pathways
|Chronic kidney disease (CKD) | Acute kidney failure | Dialysis | Secondary hyperparathyroidism (SHPT)
|Neurology and central nervous system (CNS)
|Alzheimer’s | Parkinson’s | Dementia and psychiatry | Degenerative diseases | Pain control and palliative care
|Breast cancer | Lung cancer | Chemotherapy-induced neutropenia | Intracellular signalling pathways as targets for novel treatments
|Wet age-related macular degeneration (wAMD) | Macular oedema
|Osteoporosis | Rheumatoid arthritis